Evogene Ltd.

EVGN Healthcare Biotechnology

In the quarter to June 2026, revenue fell 35.0%, EPS grew 77.4% and free cash flow grew 17.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

0.39 0.01 −2.50%
Market cap
$6.3M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
4/9
Altman Z
−20.48
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
4.45 2.25 4.07 3.24
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(2.98) (3.22) (2.54) (2.72)
P/B ratio
0.58 0.72 0.94 0.93
EV/Sales
(2.70) (1.12) (3.03) (2.40)
EV/EBITDA
0.61 0.37 0.54 0.37
EV/FCF
0.38 0.32 0.50 0.37
Current Ratio
5.11 4.54 2.79 3.57
Net Debt/EBITDA
7.91 2.56 10.62 3.85
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(43.86%) (106.36%) (180.52%) (206.82%)
Free Cash Flow Yield
(158.98%) (156.55%) (149.22%) (200.84%)
Free Cash Flow per Share
(0.38) (0.34) (0.30) (0.16)
Book value per Share
1.98 1.52 0.82 0.47
Free Cash Flow
(3.31) (2.64) (2.93) (1.89)
EV/EBIT
0.48 0.31 0.39 0.28
Other line items

Show all line items

Columns are period end dates